Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck struck an agreement with the U.S. government that includes a direct-to-patient program offering JANUVIA, JANUMET and JANUMET XR to eligible Americans at roughly 70% off current list prices and a commitment to offer the oral PCSK9 candidate enlicitide at an affordable price if approved. The company secured a three-year delay of Section 232 tariffs with the Department of Commerce to support reshoring and announced over $70 billion in planned U.S. capital and R&D spending (including at least $12 billion in capex), building on $12 billion in manufacturing investment since 2017 and $81 billion in U.S. R&D since 2018. The deal and investment plan aim to expand domestic manufacturing, lower patient costs and could influence Merck’s future revenue mix and cost structure while reducing trade-related uncertainties.

Analysis

Market structure: Merck (MRK) is the clear direct beneficiary — near-term volume upside for sitagliptin portfolio and optionality from oral PCSK9 (enlicitide) can expand addressable market versus injectable PCSK9s (AMGN, REGN). Payers and PBMs are short-term winners (lower cash prices), while incumbent injectable specialists face pricing and penetration pressure; expect 3–8% share migration in preventive cardiovascular prescriptions over 12–24 months if enlicitide gains approval and uptake. The three-year Section 232 delay reduces near-term input-cost/tariff risk and supports capital spending, which should modestly improve long-term gross-margin visibility.

Risk assessment: Tail risks include FDA rejection of enlicitide (low-probability, high-impact), expedited political moves to broader price controls (medium risk over 1–3 years), and operational execution risk from $70B capex (construction/permits, 12–36 months). Immediate market reaction will be driven in days; short-term (weeks–months) by regulatory milestones and Q/Q guidance; long-term (years) by realized manufacturing cost savings and volume ramp. Hidden dependencies: the discount program’s eligibility and payer reimbursement mechanics determine real revenue impact — a 70% list-price cut may translate to <25% net revenue decline for affected scripts depending on who pays.

Trade implications: Favor a modest constructive posture on MRK but hedge execution and regulatory risk: establish 2–3% long MRK equity weight with a 10% stop and 12-month target +15–25% if enlicitide clears FDA or guidance improves. Implement a relative-value pair: long MRK (2%) / short AMGN (1.5%) to express oral PCSK9 disruption over 6–12 months. Use options to limit capital: buy a 12-month MRK call spread (buy ATM, sell 20% OTM) sized 0.5–1% of portfolio to capture upside while capping cost; consider buying short-dated put protection if share drops >8% on earnings.

Key Decisions for Investors

• Establish a 2–3% long position in MRK (equity) within 1–2 weeks, target +15–25% over 12 months; set a 10% stop-loss and reduce to 0.5–1% if company reports >150bps gross-margin contraction in next two quarters.
• Put on a pair trade: Long MRK 2% / Short AMGN 1.5% (equal-dollar basis) to express oral-PCSK9 optionality; horizon 6–12 months, close or rebalance on an FDA decision for enlicitide or if AMGN announces a competing oral program.
• Buy a 12-month MRK call spread (buy ATM, sell 20% OTM) sized 0.5–1% of portfolio to capture upside while limiting premium; if enlicitide obtains FDA approval, roll up exposure and trim equity position to lock gains.
• If MRK credit spreads widen >25bps vs. IG peers, buy 3–5 year MRK corporate bonds (or CDS protection sold) to harvest spread compression; conversely, if spread compression is >30bps post-reshoring proof points, take profits within 6–18 months.